Last reviewed · How we verify
Amlitelimab DP1
At a glance
| Generic name | Amlitelimab DP1 |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlitelimab DP1 CI brief — competitive landscape report
- Amlitelimab DP1 updates RSS · CI watch RSS
- Sanofi portfolio CI